New mpox vaccine trial aims to protect High-Risk groups in colombia
NCT ID NCT06223919
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 20 times
Summary
This study tests whether the LC16m8 vaccine can prevent mpox in about 8,700 adults in Colombia who are at high risk, including men who have sex with men and people with HIV. Half get the vaccine right away, the other half get it later. Researchers will compare infection rates and side effects between the groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinica Universitaria Colombia - Centro Medico Teusaquillo
Bogotá, Bogota D.C., Colombia
-
Hospital Universitario San Ignacio
Bogotá, Bogota D.C., Colombia
-
Infecto Clinicos
Bogotá, Bogota D.C., Colombia
Conditions
Explore the condition pages connected to this study.